Biopharmaceutical Third Party Logistics Market by Product Type (Cell Therapies, Gene Therapies, Monoclonal Antibodies), Service Type (Distribution Management, Packaging & Labeling, Transportation), Temperature Range, Mode Of Transportation, Packaging Type
Description
The Biopharmaceutical Third Party Logistics Market was valued at USD 121.77 billion in 2024 and is projected to grow to USD 140.03 billion in 2025, with a CAGR of 15.44%, reaching USD 384.23 billion by 2032.
A concise orientation for executive stakeholders outlining critical challenges, value drivers, and strategic priorities shaping contemporary biopharmaceutical third-party logistics engagements
The biopharmaceutical third-party logistics landscape is evolving at pace, driven by the growing complexity of advanced therapies, heightened regulatory scrutiny, and rising expectations for end-to-end cold chain integrity. This introduction frames the most salient dynamics influencing vendor selection, network design, and risk management, offering executives a concise orientation to the operational and strategic priorities that define contemporary 3PL engagements. It highlights how product complexity and patient-centric supply models are reshaping value propositions for logistics partners and creating new performance criteria beyond standard delivery metrics.
Moreover, this section positions the report as a practical roadmap for leaders who must align commercial timelines with clinical supply demands. It underscores the necessity of cross-functional collaboration between manufacturing, clinical operations, quality, and commercial teams when evaluating logistics providers. By clarifying the sources of strategic differentiation and operational risk, the introduction prepares readers to interpret subsequent sections in light of tactical decision points and long-term capability investments.
How technological, regulatory, and product complexity shifts are compelling third-party logistics providers to evolve into strategic supply chain partners with advanced capabilities
Major transformative shifts are redefining how third-party logistics providers deliver value to biopharmaceutical clients, driven by converging technological, regulatory, and commercial forces. Advances in active packaging technologies and telemetry now enable real-time condition monitoring and predictive interventions, reducing spoilage risk and enabling more dynamic routing decisions. At the same time, digital orchestration platforms are facilitating greater visibility across multi-modal networks, allowing shippers to coordinate handoffs, automate compliance documentation, and trigger contingency flows when excursions are detected.
In parallel, the sector is adjusting to new product modalities that demand specialized handling, such as cell and gene therapies that require controlled atmospheres and ultra-low temperature logistics. Regulatory expectations around traceability and temperature control continue to crystallize, prompting providers to adopt standardized validation frameworks and to invest in audit-ready data capture. Transitioning from transactional logistics to partnership-based models, the best providers are positioning themselves as integrated supply chain advisors that support clinical supply continuity, commercial launches, and lifecycle management for biologic products.
What the 2025 United States tariff adjustments mean for route selection, modal optimization, duty management, and network resiliency for biologic cold chain logistics
The introduction of tariff adjustments in the United States for 2025 is materially influencing route selection, modal choice, and contract structures within the biopharmaceutical logistics ecosystem. Firms are reassessing cost-to-serve calculations and evaluating the trade-offs between direct air lanes, intermodal alternatives, and regional distribution hubs to mitigate tariff impacts without compromising cold chain integrity. This rebalancing often involves deeper collaboration between procurement, customs specialists, and logistics partners to redesign corridors and to identify duty optimization opportunities consistent with regulatory compliance.
As a result, decision-makers are prioritizing scenario planning and stress-testing of network designs against tariff-induced cost differentials. Tactical responses include renegotiating service level agreements to incorporate tariff contingencies, revising incoterms where feasible, and expanding the use of bonded facilities to defer duties. Longer term, organizations are also exploring nearshoring and regionalization strategies to reduce exposure to tariff volatility, while ensuring that any changes maintain the rigorous handling and documentation standards necessary for biologic therapies.
A layered segmentation framework revealing how service types, temperature controls, transport modes, end users, product modalities, and packaging choices determine logistics requirements
Segmentation analysis reveals the nuanced ways in which service capabilities, temperature regimes, transportation modes, end users, product types, and packaging choices intersect to shape provider selection and operational planning. Based on Service Type the market is studied across Distribution Management, Packaging & Labeling, Transportation, and Warehousing; within Packaging & Labeling the focus extends to Active Packaging, Labeling Services, and Passive Packaging, while Active Packaging further subdivides into Controlled Atmosphere Packaging and Refrigerated Containers. Transportation is parsed into Air Transport, Rail Transport, Road Transport, and Sea Transport with Air Transport distinguishing between Express Air and Standard Air, and Warehousing separating Ambient Storage Warehousing from Cold Storage Warehousing.
Based on Temperature Range the analysis considers Ambient, Chilled, Controlled Room Temperature, and Frozen categories, with Chilled differentiated into Monitored Chilled and Standard Chilled, Controlled Room Temperature into Monitored Controlled Room Temperature and Standard Controlled Room Temperature, and Frozen split between Standard Frozen and Ultra Frozen. Based on Mode Of Transportation the taxonomy includes Air Freight, Rail Freight, Road Transport, and Sea Freight, with Air Freight delineated into Express Air and Standard Air, Road Transport into Full Truck Load and Less Than Truck Load, and Sea Freight into Full Container Load and Less Than Container Load. Based on End User the study covers Biopharmaceutical Manufacturers, Contract Manufacturing Organizations, Contract Research Organizations, Diagnostic Laboratories, and Hospitals & Clinics, with Hospitals & Clinics further defined as Community Hospitals and Research Hospitals. Based on Product Type the market is examined across Cell Therapies, Gene Therapies, Monoclonal Antibodies, Recombinant Proteins, and Vaccines, with Cell Therapies split between Dendritic Cell Therapies and Stem Cell Therapies and Vaccines into Inactivated and Live Attenuated. Finally, Based on Packaging Type the segmentation considers Active Packaging and Passive Packaging, with Active Packaging including Refrigerated Containers and Temperature Controlled Shippers and Passive Packaging comprising Insulated Boxes and Thermal Blankets. This layered segmentation underscores how discrete operational requirements and regulatory obligations vary by therapy, handling condition, and stakeholder, informing provider capability assessments and contractual terms.
How regional regulatory, infrastructure, and commercial differences across the Americas, Europe Middle East & Africa, and Asia-Pacific shape logistics strategy and capability investments
Regional dynamics create differentiated operational imperatives for third-party logistics providers as they support biopharmaceutical distribution across distinct regulatory regimes, infrastructure landscapes, and commercial ecosystems. In the Americas, logistics networks frequently prioritize speed and integrated customs facilitation to support cross-border clinical supplies and commercial launches, relying on sophisticated air cargo lanes and bonded warehousing to maintain cold chain continuity. The presence of major biotech clusters and concentrated manufacturing footprints drives demand for agile last-mile solutions and temperature-mapped storage capacity that aligns with clinical timelines and commercial distribution windows.
In Europe, Middle East & Africa the landscape is shaped by a complex mosaic of regulatory frameworks and long-distance trade corridors, which elevates the importance of harmonized documentation, validated transit pathways, and partners capable of navigating multi-jurisdictional compliance. Providers operating across this region often emphasize interoperability of data systems and regional consolidation strategies to reduce handling points. In the Asia-Pacific region, expansive manufacturing bases and emerging biopharma hubs are prompting investments in cold storage infrastructure and intermodal connectivity, while rapid urbanization creates unique last-mile challenges. Across all regions, providers must adapt to local regulatory nuances while delivering standardized quality systems that support global product integrity.
Insights into competitive differentiation where specialized assets, digital orchestration, and validated cold chain capabilities determine supplier selection and partnership value
Competitive dynamics among key companies reveal strategic positioning around specialized assets, digital orchestration, and vertical integration of services. Leading providers are differentiating through investments in active packaging solutions, telemetry-enabled shippers, and validated cold storage nodes that support ultra-low temperature requirements. Others are competing on network breadth and multimodal flexibility, enabling customers to switch between air, sea, and road alternatives without degrading chain-of-custody assurance. Strategic alliances between logistics providers and packaging innovators are accelerating the adoption of reusable temperature-controlled shippers that lower total cost of ownership while maintaining regulatory compliance.
Beyond hardware and network reach, the strongest competitors emphasize service orchestration capabilities that integrate compliance documentation, product serialization, and real-time exception management. These providers offer modular service bundles that align with clinical protocol needs and commercial distribution profiles, enabling sponsors and manufacturers to procure tailored solutions rather than one-size-fits-all offerings. For buyers, supplier evaluation increasingly centers on demonstrated experience with complex biologics, validated processes for controlled atmosphere handling, and a track record of successful regulatory inspections and audits.
A pragmatic set of prioritized actions for industry leaders to strengthen resilience, align sourcing with product complexity, and operationalize predictive cold chain controls
Leaders in the industry should pursue a clear set of actionable measures to enhance resilience, reduce operational risk, and capture value from evolving product and regulatory requirements. First, prioritize investments in telemetry and data analytics that convert temperature and location signals into predictive alerts and performance KPIs, enabling proactive exception management and continuous improvement of transport corridors. Second, align contractual terms with contingency planning requirements, ensuring that service level agreements explicitly define responsibilities for excursions, reshipment, and regulatory documentation to minimize ambiguity during disruptions.
Third, adopt a capability-driven sourcing strategy that evaluates providers against the specific requirements of product types, temperature ranges, and end-user needs rather than solely on price. Fourth, implement cross-functional playbooks that coordinate supply chain, quality, regulatory, and clinical teams for faster decision-making when deviations occur. Finally, consider regionalization and nearshoring scenarios where tariff and trade dynamics warrant local inventory positioning, but only after ensuring that local providers meet global quality and validation standards. Taken together, these steps create a pragmatic roadmap to reduce risk exposure while enabling scalable support for innovative therapies.
A robust mixed-methods methodology combining expert consultations, capability mapping, and scenario-based analyses to validate operational insights and best practices
The research methodology underpinning this executive summary combines qualitative expert interviews, primary stakeholder consultations, and a structured analysis of operational practices observed across leading logistics networks. Primary inputs include discussions with supply chain executives, regulatory affairs specialists, packaging technologists, and clinical operations leaders to surface current pain points and capability gaps. These insights were triangulated with secondary sources such as regulatory guidance documents, industry white papers, and vendor technical specifications to validate observed trends and to ensure the analysis reflects current compliance expectations and technology capabilities.
Analytical methods emphasize capability mapping, scenario-based stress testing for tariffs and modal shifts, and comparative assessments of packaging and warehousing solutions. The approach privileges evidence of validated processes, audit outcomes, and documented performance in handling complex biologics over vendor claims. Where appropriate, the methodology highlights case-based learnings that illustrate successful mitigations for cold chain failures and best practices for multi-modal orchestration, enabling readers to apply practical lessons to their own network designs.
A decisive synthesis emphasizing capability-based sourcing, validated cold chain investments, and collaborative contingency planning to protect biologic product integrity and access
In conclusion, the converging pressures of advanced therapeutic modalities, regulatory rigor, and shifting trade dynamics are reshaping expectations for third-party logistics in the biopharmaceutical sector. Providers that combine validated cold chain infrastructure with telemetry-enabled packaging, interoperable data systems, and deep regulatory expertise will emerge as preferred partners for sponsors and manufacturers. At the same time, procurement and supply chain leaders must move beyond cost-centric evaluations to adopt capability-driven sourcing frameworks that account for therapy-specific handling requirements and regional compliance nuances.
Ultimately, success in this environment depends on proactive collaboration between shippers and logistics partners to co-develop contingency plans, to validate operational processes, and to invest in technologies that convert operational data into tactical advantage. By aligning strategic priorities with targeted capability investments, biopharmaceutical organizations can reduce distribution risk, protect product quality, and support timely access for patients.
Note: PDF & Excel + Online Access - 1 Year
A concise orientation for executive stakeholders outlining critical challenges, value drivers, and strategic priorities shaping contemporary biopharmaceutical third-party logistics engagements
The biopharmaceutical third-party logistics landscape is evolving at pace, driven by the growing complexity of advanced therapies, heightened regulatory scrutiny, and rising expectations for end-to-end cold chain integrity. This introduction frames the most salient dynamics influencing vendor selection, network design, and risk management, offering executives a concise orientation to the operational and strategic priorities that define contemporary 3PL engagements. It highlights how product complexity and patient-centric supply models are reshaping value propositions for logistics partners and creating new performance criteria beyond standard delivery metrics.
Moreover, this section positions the report as a practical roadmap for leaders who must align commercial timelines with clinical supply demands. It underscores the necessity of cross-functional collaboration between manufacturing, clinical operations, quality, and commercial teams when evaluating logistics providers. By clarifying the sources of strategic differentiation and operational risk, the introduction prepares readers to interpret subsequent sections in light of tactical decision points and long-term capability investments.
How technological, regulatory, and product complexity shifts are compelling third-party logistics providers to evolve into strategic supply chain partners with advanced capabilities
Major transformative shifts are redefining how third-party logistics providers deliver value to biopharmaceutical clients, driven by converging technological, regulatory, and commercial forces. Advances in active packaging technologies and telemetry now enable real-time condition monitoring and predictive interventions, reducing spoilage risk and enabling more dynamic routing decisions. At the same time, digital orchestration platforms are facilitating greater visibility across multi-modal networks, allowing shippers to coordinate handoffs, automate compliance documentation, and trigger contingency flows when excursions are detected.
In parallel, the sector is adjusting to new product modalities that demand specialized handling, such as cell and gene therapies that require controlled atmospheres and ultra-low temperature logistics. Regulatory expectations around traceability and temperature control continue to crystallize, prompting providers to adopt standardized validation frameworks and to invest in audit-ready data capture. Transitioning from transactional logistics to partnership-based models, the best providers are positioning themselves as integrated supply chain advisors that support clinical supply continuity, commercial launches, and lifecycle management for biologic products.
What the 2025 United States tariff adjustments mean for route selection, modal optimization, duty management, and network resiliency for biologic cold chain logistics
The introduction of tariff adjustments in the United States for 2025 is materially influencing route selection, modal choice, and contract structures within the biopharmaceutical logistics ecosystem. Firms are reassessing cost-to-serve calculations and evaluating the trade-offs between direct air lanes, intermodal alternatives, and regional distribution hubs to mitigate tariff impacts without compromising cold chain integrity. This rebalancing often involves deeper collaboration between procurement, customs specialists, and logistics partners to redesign corridors and to identify duty optimization opportunities consistent with regulatory compliance.
As a result, decision-makers are prioritizing scenario planning and stress-testing of network designs against tariff-induced cost differentials. Tactical responses include renegotiating service level agreements to incorporate tariff contingencies, revising incoterms where feasible, and expanding the use of bonded facilities to defer duties. Longer term, organizations are also exploring nearshoring and regionalization strategies to reduce exposure to tariff volatility, while ensuring that any changes maintain the rigorous handling and documentation standards necessary for biologic therapies.
A layered segmentation framework revealing how service types, temperature controls, transport modes, end users, product modalities, and packaging choices determine logistics requirements
Segmentation analysis reveals the nuanced ways in which service capabilities, temperature regimes, transportation modes, end users, product types, and packaging choices intersect to shape provider selection and operational planning. Based on Service Type the market is studied across Distribution Management, Packaging & Labeling, Transportation, and Warehousing; within Packaging & Labeling the focus extends to Active Packaging, Labeling Services, and Passive Packaging, while Active Packaging further subdivides into Controlled Atmosphere Packaging and Refrigerated Containers. Transportation is parsed into Air Transport, Rail Transport, Road Transport, and Sea Transport with Air Transport distinguishing between Express Air and Standard Air, and Warehousing separating Ambient Storage Warehousing from Cold Storage Warehousing.
Based on Temperature Range the analysis considers Ambient, Chilled, Controlled Room Temperature, and Frozen categories, with Chilled differentiated into Monitored Chilled and Standard Chilled, Controlled Room Temperature into Monitored Controlled Room Temperature and Standard Controlled Room Temperature, and Frozen split between Standard Frozen and Ultra Frozen. Based on Mode Of Transportation the taxonomy includes Air Freight, Rail Freight, Road Transport, and Sea Freight, with Air Freight delineated into Express Air and Standard Air, Road Transport into Full Truck Load and Less Than Truck Load, and Sea Freight into Full Container Load and Less Than Container Load. Based on End User the study covers Biopharmaceutical Manufacturers, Contract Manufacturing Organizations, Contract Research Organizations, Diagnostic Laboratories, and Hospitals & Clinics, with Hospitals & Clinics further defined as Community Hospitals and Research Hospitals. Based on Product Type the market is examined across Cell Therapies, Gene Therapies, Monoclonal Antibodies, Recombinant Proteins, and Vaccines, with Cell Therapies split between Dendritic Cell Therapies and Stem Cell Therapies and Vaccines into Inactivated and Live Attenuated. Finally, Based on Packaging Type the segmentation considers Active Packaging and Passive Packaging, with Active Packaging including Refrigerated Containers and Temperature Controlled Shippers and Passive Packaging comprising Insulated Boxes and Thermal Blankets. This layered segmentation underscores how discrete operational requirements and regulatory obligations vary by therapy, handling condition, and stakeholder, informing provider capability assessments and contractual terms.
How regional regulatory, infrastructure, and commercial differences across the Americas, Europe Middle East & Africa, and Asia-Pacific shape logistics strategy and capability investments
Regional dynamics create differentiated operational imperatives for third-party logistics providers as they support biopharmaceutical distribution across distinct regulatory regimes, infrastructure landscapes, and commercial ecosystems. In the Americas, logistics networks frequently prioritize speed and integrated customs facilitation to support cross-border clinical supplies and commercial launches, relying on sophisticated air cargo lanes and bonded warehousing to maintain cold chain continuity. The presence of major biotech clusters and concentrated manufacturing footprints drives demand for agile last-mile solutions and temperature-mapped storage capacity that aligns with clinical timelines and commercial distribution windows.
In Europe, Middle East & Africa the landscape is shaped by a complex mosaic of regulatory frameworks and long-distance trade corridors, which elevates the importance of harmonized documentation, validated transit pathways, and partners capable of navigating multi-jurisdictional compliance. Providers operating across this region often emphasize interoperability of data systems and regional consolidation strategies to reduce handling points. In the Asia-Pacific region, expansive manufacturing bases and emerging biopharma hubs are prompting investments in cold storage infrastructure and intermodal connectivity, while rapid urbanization creates unique last-mile challenges. Across all regions, providers must adapt to local regulatory nuances while delivering standardized quality systems that support global product integrity.
Insights into competitive differentiation where specialized assets, digital orchestration, and validated cold chain capabilities determine supplier selection and partnership value
Competitive dynamics among key companies reveal strategic positioning around specialized assets, digital orchestration, and vertical integration of services. Leading providers are differentiating through investments in active packaging solutions, telemetry-enabled shippers, and validated cold storage nodes that support ultra-low temperature requirements. Others are competing on network breadth and multimodal flexibility, enabling customers to switch between air, sea, and road alternatives without degrading chain-of-custody assurance. Strategic alliances between logistics providers and packaging innovators are accelerating the adoption of reusable temperature-controlled shippers that lower total cost of ownership while maintaining regulatory compliance.
Beyond hardware and network reach, the strongest competitors emphasize service orchestration capabilities that integrate compliance documentation, product serialization, and real-time exception management. These providers offer modular service bundles that align with clinical protocol needs and commercial distribution profiles, enabling sponsors and manufacturers to procure tailored solutions rather than one-size-fits-all offerings. For buyers, supplier evaluation increasingly centers on demonstrated experience with complex biologics, validated processes for controlled atmosphere handling, and a track record of successful regulatory inspections and audits.
A pragmatic set of prioritized actions for industry leaders to strengthen resilience, align sourcing with product complexity, and operationalize predictive cold chain controls
Leaders in the industry should pursue a clear set of actionable measures to enhance resilience, reduce operational risk, and capture value from evolving product and regulatory requirements. First, prioritize investments in telemetry and data analytics that convert temperature and location signals into predictive alerts and performance KPIs, enabling proactive exception management and continuous improvement of transport corridors. Second, align contractual terms with contingency planning requirements, ensuring that service level agreements explicitly define responsibilities for excursions, reshipment, and regulatory documentation to minimize ambiguity during disruptions.
Third, adopt a capability-driven sourcing strategy that evaluates providers against the specific requirements of product types, temperature ranges, and end-user needs rather than solely on price. Fourth, implement cross-functional playbooks that coordinate supply chain, quality, regulatory, and clinical teams for faster decision-making when deviations occur. Finally, consider regionalization and nearshoring scenarios where tariff and trade dynamics warrant local inventory positioning, but only after ensuring that local providers meet global quality and validation standards. Taken together, these steps create a pragmatic roadmap to reduce risk exposure while enabling scalable support for innovative therapies.
A robust mixed-methods methodology combining expert consultations, capability mapping, and scenario-based analyses to validate operational insights and best practices
The research methodology underpinning this executive summary combines qualitative expert interviews, primary stakeholder consultations, and a structured analysis of operational practices observed across leading logistics networks. Primary inputs include discussions with supply chain executives, regulatory affairs specialists, packaging technologists, and clinical operations leaders to surface current pain points and capability gaps. These insights were triangulated with secondary sources such as regulatory guidance documents, industry white papers, and vendor technical specifications to validate observed trends and to ensure the analysis reflects current compliance expectations and technology capabilities.
Analytical methods emphasize capability mapping, scenario-based stress testing for tariffs and modal shifts, and comparative assessments of packaging and warehousing solutions. The approach privileges evidence of validated processes, audit outcomes, and documented performance in handling complex biologics over vendor claims. Where appropriate, the methodology highlights case-based learnings that illustrate successful mitigations for cold chain failures and best practices for multi-modal orchestration, enabling readers to apply practical lessons to their own network designs.
A decisive synthesis emphasizing capability-based sourcing, validated cold chain investments, and collaborative contingency planning to protect biologic product integrity and access
In conclusion, the converging pressures of advanced therapeutic modalities, regulatory rigor, and shifting trade dynamics are reshaping expectations for third-party logistics in the biopharmaceutical sector. Providers that combine validated cold chain infrastructure with telemetry-enabled packaging, interoperable data systems, and deep regulatory expertise will emerge as preferred partners for sponsors and manufacturers. At the same time, procurement and supply chain leaders must move beyond cost-centric evaluations to adopt capability-driven sourcing frameworks that account for therapy-specific handling requirements and regional compliance nuances.
Ultimately, success in this environment depends on proactive collaboration between shippers and logistics partners to co-develop contingency plans, to validate operational processes, and to invest in technologies that convert operational data into tactical advantage. By aligning strategic priorities with targeted capability investments, biopharmaceutical organizations can reduce distribution risk, protect product quality, and support timely access for patients.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
182 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Adoption of AI-driven real-time temperature monitoring solutions to ensure biologic stability during cold chain logistics
- 5.2. Expansion of specialized GDP-compliant facilities to support cell and gene therapy storage and distribution requirements
- 5.3. Implementation of digital twin technology for predictive modeling of complex biopharma supply chain disruptions
- 5.4. Collaboration between 3PL providers and regulatory bodies to streamline serialization and track-and-trace compliance
- 5.5. Development of multi-modal transportation networks integrating air, sea, and ground to optimize cold chain efficiency globally
- 5.6. Investment in sustainable cold chain packaging solutions to reduce carbon footprint and maintain product integrity over long distances
- 5.7. Adoption of blockchain-enabled platforms for enhanced transparency in biologics provenance and temperature excursion tracking
- 5.8. Rising demand for end-to-end visibility platforms integrating IoT sensors and cloud analytics in temperature-sensitive shipments
- 5.9. Strategic partnerships for last-mile delivery customized to hospital and clinical trial requirements in mRNA vaccine distribution
- 5.10. Growth of on-demand warehousing models offering scalable capacity and flexible lease terms for biopharma distribution networks
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Biopharmaceutical Third Party Logistics Market, by Product Type
- 8.1. Cell Therapies
- 8.1.1. Dendritic Cell Therapies
- 8.1.2. Stem Cell Therapies
- 8.2. Gene Therapies
- 8.3. Monoclonal Antibodies
- 8.4. Recombinant Proteins
- 8.5. Vaccines
- 8.5.1. Inactivated
- 8.5.2. Live Attenuated
- 9. Biopharmaceutical Third Party Logistics Market, by Service Type
- 9.1. Distribution Management
- 9.2. Packaging & Labeling
- 9.2.1. Active Packaging
- 9.2.1.1. Controlled Atmosphere Packaging
- 9.2.1.2. Refrigerated Containers
- 9.2.2. Labeling Services
- 9.2.3. Passive Packaging
- 9.3. Transportation
- 9.3.1. Air Transport
- 9.3.1.1. Express Air
- 9.3.1.2. Standard Air
- 9.3.2. Rail Transport
- 9.3.3. Road Transport
- 9.3.4. Sea Transport
- 9.4. Warehousing
- 9.4.1. Ambient Storage Warehousing
- 9.4.2. Cold Storage Warehousing
- 10. Biopharmaceutical Third Party Logistics Market, by Temperature Range
- 10.1. Ambient
- 10.2. Chilled
- 10.2.1. Monitored Chilled
- 10.2.2. Standard Chilled
- 10.3. Controlled Room Temperature
- 10.3.1. Monitored Controlled Room Temperature
- 10.3.2. Standard Controlled Room Temperature
- 10.4. Frozen
- 10.4.1. Standard Frozen
- 10.4.2. Ultra Frozen
- 11. Biopharmaceutical Third Party Logistics Market, by Mode Of Transportation
- 11.1. Air Freight
- 11.1.1. Express Air
- 11.1.2. Standard Air
- 11.2. Rail Freight
- 11.3. Road Transport
- 11.3.1. Full Truck Load
- 11.3.2. Less Than Truck Load
- 11.4. Sea Freight
- 11.4.1. Full Container Load
- 11.4.2. Less Than Container Load
- 12. Biopharmaceutical Third Party Logistics Market, by Packaging Type
- 12.1. Active Packaging
- 12.1.1. Refrigerated Containers
- 12.1.2. Temperature Controlled Shippers
- 12.2. Passive Packaging
- 12.2.1. Insulated Boxes
- 12.2.2. Thermal Blankets
- 13. Biopharmaceutical Third Party Logistics Market, by End User
- 13.1. Biopharmaceutical Manufacturers
- 13.2. Contract Manufacturing Organizations
- 13.3. Contract Research Organizations
- 13.4. Diagnostic Laboratories
- 13.5. Hospitals & Clinics
- 13.5.1. Community Hospitals
- 13.5.2. Research Hospitals
- 14. Biopharmaceutical Third Party Logistics Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Biopharmaceutical Third Party Logistics Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Biopharmaceutical Third Party Logistics Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. Agility Public Warehousing Company K.S.C.P.
- 17.3.2. Bolloré SE
- 17.3.3. C.H. Robinson Worldwide, Inc.
- 17.3.4. Cardinal Health, Inc.
- 17.3.5. Cencora, Inc.
- 17.3.6. CEVA Logistics AG
- 17.3.7. Cryoport, Inc.
- 17.3.8. DB Schenker Logistics Germany AG & Co. KG
- 17.3.9. Deutsche Post AG
- 17.3.10. DSV Panalpina A/S
- 17.3.11. EVERSANA Life Science Services LLC
- 17.3.12. Expeditors International of Washington, Inc.
- 17.3.13. FedEx Corporation
- 17.3.14. KLN Logistics Group Limited
- 17.3.15. Kuehne + Nagel International AG
- 17.3.16. LOGISTEED, Ltd.
- 17.3.17. McKesson Corporation
- 17.3.18. NIPPON EXPRESS HOLDINGS, INC.
- 17.3.19. SF Holding Co., Ltd.
- 17.3.20. Thermo Fisher Scientific Inc.
- 17.3.21. United Parcel Service, Inc.
- 17.3.22. XPO, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
